Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2016 Jul 25

PMID 27449869

Citations 85

Authors

Catriona S Bradshaw

Jack D Sobel

Affiliations

Soon will be listed here.

Abstract

Practitioners and patients alike widely recognize the limitations of current therapeutic approaches to the treatment of bacterial vaginosis (BV). Options remain extremely limited, and our inability to prevent the frequently, often relentless symptomatic recurrences of BV and to reduce serious sequelae such as preterm delivery, remains an acknowledged but unresolved shortcoming. Our incomplete understanding of the pathophysiology of this unique form of vaginal dysbiosis has been a significant impediment to developing optimal treatment and prevention approaches. New drugs have not been forthcoming and are not likely to be available in the immediate future; hence, reliance on the optimal use of available agents has become essential as improvised often unproven regimens are implemented. In this review, we will explore the limitations of currently recommended therapies, with a particular focus on the contribution of reinfection and pathogen persistence to BV recurrence, and the development of interventions that target these mechanisms. Ultimately, to achieve sustained cure and effectiveness against BV-associated sequelae, it is possible that we will need approaches that combine antimicrobials with biofilm-disrupting agents and partner treatments in those at risk of reinfection.

Citing Articles

Comparing the efficacy of probiotic plus antibiotic with the Antibiotic Therapy alone on the recurrence of Bacterial Vaginosis.

Ashraf S, Haroon A, Fayyaz A Pak J Med Sci. 2025; 41(1):125-129.

PMID: 39867779 PMC: 11755309. DOI: 10.12669/pjms.41.1.9922.

Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial.

Gill B, Wessels J, Hayes C, Ratcliffe J, Wokuri J, Ball E PLoS One. 2025; 20(1):e0315576.

PMID: 39836666 PMC: 11750099. DOI: 10.1371/journal.pone.0315576.

Evaluation of Metronidazole Resistance of Vaginal Swab Isolates from South African Women Treated for Bacterial Vaginosis.

Schwebs T, Kieninger A, Podpera Tisakova L, Oberbauer V, Berdaguer R, Mtshali A Antibiotics (Basel). 2025; 13(12.

PMID: 39766607 PMC: 11672489. DOI: 10.3390/antibiotics13121217.

Vaginal Microbiome: Environmental, Biological, and Racial Influences on Gynecological Health Across the Lifespan.

Dube-Zinatelli E, Cappelletti L, Ismail N Am J Reprod Immunol. 2024; 92(6):e70026.

PMID: 39670915 PMC: 11640209. DOI: 10.1111/aji.70026.

Effect of metronidazole on concentrations of vaginal bacteria associated with risk of HIV acquisition.

Valint D, Fiedler T, Liu C, Srinivasan S, Fredricks D mBio. 2024; 15(12):e0111024.

PMID: 39570045 PMC: 11633388. DOI: 10.1128/mbio.01110-24.

References

Ferris M, Masztal A, Aldridge K, Fortenberry J, Fidel Jr P, Martin D . Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis. 2004; 4:5. PMC: 362875. DOI: 10.1186/1471-2334-4-5. View

Balkus J, Richardson B, Mochache V, Chohan V, Chan J, Masese L . A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women. Sex Transm Dis. 2013; 40(6):499-505. PMC: 3676301. DOI: 10.1097/OLQ.0b013e31828fce34. View

Vejtorp M, Bollerup A, Vejtorp L, FANOE E, Nathan E, Reiter A . Bacterial vaginosis: a double-blind randomized trial of the effect of treatment of the sexual partner. Br J Obstet Gynaecol. 1988; 95(9):920-6. DOI: 10.1111/j.1471-0528.1988.tb06581.x. View

Myer L, Kuhn L, Stein Z, Wright Jr T, Denny L . Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis. 2005; 5(12):786-94. DOI: 10.1016/S1473-3099(05)70298-X. View

Bradshaw C, Walker S, Vodstrcil L, Bilardi J, Law M, Hocking J . The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW Health Study. J Infect Dis. 2013; 209(10):1562-72. DOI: 10.1093/infdis/jit664. View

Bump R, Buesching 3rd W . Bacterial vaginosis in virginal and sexually active adolescent females: evidence against exclusive sexual transmission. Am J Obstet Gynecol. 1988; 158(4):935-9. DOI: 10.1016/0002-9378(88)90097-x. View

Sobel J, Ferris D, Schwebke J, Nyirjesy P, Wiesenfeld H, Peipert J . Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006; 194(5):1283-9. DOI: 10.1016/j.ajog.2005.11.041. View

Sanchez S, Garcia P, Thomas K, Catlin M, Holmes K . Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol. 2004; 191(6):1898-906. DOI: 10.1016/j.ajog.2004.06.089. View

Deng Y, Lim A, Lee J, Chen S, An S, Dong Y . Diffusible signal factor (DSF) quorum sensing signal and structurally related molecules enhance the antimicrobial efficacy of antibiotics against some bacterial pathogens. BMC Microbiol. 2014; 14:51. PMC: 3941561. DOI: 10.1186/1471-2180-14-51. View

10.

Colli E, Landoni M, Parazzini F . Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial. Genitourin Med. 1997; 73(4):267-70. PMC: 1195855. DOI: 10.1136/sti.73.4.267. View

11.

Yildirim S, Yeoman C, Janga S, Thomas S, Ho M, Leigh S . Primate vaginal microbiomes exhibit species specificity without universal Lactobacillus dominance. ISME J. 2014; 8(12):2431-44. PMC: 4260710. DOI: 10.1038/ismej.2014.90. View

12.

Schwebke J, Desmond R . A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. 2006; 44(2):213-9. DOI: 10.1086/509577. View

13.

Hymes S, Randis T, Sun T, Ratner A . DNase inhibits Gardnerella vaginalis biofilms in vitro and in vivo. J Infect Dis. 2013; 207(10):1491-7. PMC: 3627197. DOI: 10.1093/infdis/jit047. View

14.

Swidsinski A, Dorffel Y, Loening-Baucke V, Schilling J, Mendling W . Response of Gardnerella vaginalis biofilm to 5 days of moxifloxacin treatment. FEMS Immunol Med Microbiol. 2010; 61(1):41-6. DOI: 10.1111/j.1574-695X.2010.00743.x. View

15.

Muzny C, Schwebke J . Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections. Clin Infect Dis. 2015; 61(4):601-6. PMC: 4607736. DOI: 10.1093/cid/civ353. View

16.

Hillier S, Nugent R, Eschenbach D, Krohn M, Gibbs R, Martin D . Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med. 1995; 333(26):1737-42. DOI: 10.1056/NEJM199512283332604. View

17.

Senok A, Verstraelen H, Temmerman M, Botta G . Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev. 2009; (4):CD006289. DOI: 10.1002/14651858.CD006289.pub2. View

18.

Yen S, Shafer M, Moncada J, Campbell C, Flinn S, Boyer C . Bacterial vaginosis in sexually experienced and non-sexually experienced young women entering the military. Obstet Gynecol. 2003; 102(5 Pt 1):927-33. DOI: 10.1016/s0029-7844(03)00858-5. View

19.

Bradshaw C, Morton A, Hocking J, Garland S, Morris M, Moss L . High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006; 193(11):1478-86. DOI: 10.1086/503780. View

20.

Bradshaw C, Morton A, Garland S, Morris M, Moss L, Fairley C . Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol. 2005; 106(1):105-14. DOI: 10.1097/01.AOG.0000163247.78533.7b. View